Skip to main content

Table 5 Median and range for PSQI by treatment, with p-value and standardized effect size, d

From: Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)

Measure

Treatment

A: Placebo

B: Melatonin

p

D

Median

Range

Median

Range

Overall Score

9.0

2–13

8.0

2–16

0.893

0.036

Sleep Disturbances

2.0

1–3

2.0

1–3

0.092

0.471

Sleep Medication

0.0

0–0

0.0

0–3

0.228

0.333

Sleep Duration

1.0

0–3

1.0

0–3

0.663

0.119

Sleep Latency

1.0

0–5

1.0

0–3

0.927

0.025

Sleep Quality

1.0

0–3

1.0

0–3

0.922

0.027

Daytime Dysfunction

1.0

0–3

1.0

1–3

0.141

0.410

Habitual Sleep Efficiency

2.0

0–3

1.0

0–3

0.114

0.440